All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Normal excitation-contraction coupling in skeletal and cardiac myocytes requires that the relative arrangement of integral membrane proteins remains unperturbed throughout the contraction cycle. Some of these membrane proteins facilitate structural continuity between adjacent myocytes, while other membrane proteins mediate the ionic flux that underlies excitation-contraction coupling. Adaptor proteins like ankyrin are critical for the retention and scaffolding of integral membrane proteins to the underlying cytoskeleton. By scaffolding specific membrane proteins and signaling molecules, ankyrins also contribute to the functional specialization of subcellular domains within myocytes.

Alternative splicing of an ankyrin gene produces different isoforms that display unique functions and subcellular distribution. In fact, alternative splicing of the *Ank3* gene results in numerous ankyrin-G isoforms that have been detected in various tissues including brain, skeletal muscle, lung, and kidney \[[@pone.0128177.ref001]--[@pone.0128177.ref006]\]. In heart, only one ankyrin-G isoform has been characterized, yet numerous membrane proteins have been shown to interact with ankyrin-G including connexin 43, β dystroglycan, and voltage-gated sodium channels \[[@pone.0128177.ref007]--[@pone.0128177.ref012]\]. These membrane proteins are expressed at distinct membrane domains in ventricular cardiomyocytes such as the intercalated disc, transverse(T)-tubule, and costamere \[[@pone.0128177.ref007], [@pone.0128177.ref008], [@pone.0128177.ref010]--[@pone.0128177.ref012]\]. Considering these findings, we hypothesize that the heart expresses more than one isoform of ankyrin-G.

This study is the first to report the comprehensive analysis of *Ank3* expression and alternative splicing in the heart. We demonstrate that the heart expresses multiple ankyrin-G isoforms and that ankyrin-G isoforms are detected at the intercalated discs and T-tubules of individually isolated cardiomyocytes. Using a PCR-based screen of cardiac mRNA, we identify two new exons in the *Ank3* gene and 28 novel splicing events in *Ank3* transcripts. We measure the relative ventricular expression of each splice junction by quantitative real-time PCR with transcript-specific primers. We demonstrate that expression of exon 1d, one of the five first *Ank3* exons, is restricted to heart and skeletal muscle. We evaluate some of the alternative splice isoforms for altered function and find that two rare isoforms of the ankyrin-G spectrin-binding domain lack spectrin binding. In summary, this study demonstrates that the *Ank3* gene is subject to complex splicing regulation resulting in numerous ankyrin-G isoforms in heart. We anticipate that these different isoforms underlie the diversity of ankyrin-G functions and subcellular distribution within cardiomyocytes.

Materials and Methods {#sec002}
=====================

RNA isolation, reverse transcription, and PCR amplification of *Ank3* transcripts {#sec003}
---------------------------------------------------------------------------------

RNA was isolated from mouse tissues with GenEluteMammalian RNA kit (Sigma Aldrich). cDNA was synthesized using SuperScript III (Life Technologies). *Ank3* transcripts were amplified using nine overlapping primer sets using Phusion polymerase (Finnzymes) from mouse heart cDNA. PCR products were purified, ligated into pCR2.1-TOPO vector (Life Technologies), and sequenced.

Quantitative RT-PCR analysis of alternative *Ank3* transcripts {#sec004}
--------------------------------------------------------------

Exon-exon boundary spanning primers containing \~12 base pairs from each exon were designed to PCR-amplify specific *Ank3* splice junctions as previously described \[[@pone.0128177.ref013]\]. cDNA was synthesized from mRNA isolated from three age- and sex-matched mice. For each primer set, quantitative rt-PCR was performed in triplicate using SYBR Green Jumpstart Taq mix (Sigma Aldrich) and experiments were repeated three times. Analysis of the data was performed using a modified version of the Pfaffl method to incorporate primer efficiencies \[[@pone.0128177.ref014]\]. First, alternative *Ank3* splice junctions were grouped according to shared exons (e.g. E15/16 is grouped with E15/17). The fold difference was determined using the highest threshold cycle (C~T~) value within that group as a reference. Percentage of abundance of each junction was calculated by comparing the C~T~ value of that junction to the sum of all C~T~ values for that group (e.g. the sum of E15/16 and E15/17 equal 100%). All errors were propagated through the fold difference and percentage calculations as standard deviations. The results were graphed with individual bars representing the average of a technical replicate and error bars represent standard deviations. Nucleotide sequences, amplicon lengths, annealing temperatures, and efficiencies for qt-PCR primer sets are listed in [S1 Table](#pone.0128177.s002){ref-type="supplementary-material"}.

Molecular cloning of β-spectrins, ankyrin-G SBD and CTD variants {#sec005}
----------------------------------------------------------------

Spectrin repeats 13 to 17 of β1- and β2-spectrins were PCR-amplified from heart cDNA using primers for β1-spectrin (`TCTATGTCATCTCCGATGAGATCCC, CTACAGTGACTCCCAGGAACTAGAC`) and β2-spectrin (`AGAGTGCTGTCTCCATGTTG, CTAAGTATCCCACTGCTGCTGGGA`). PCR products were sequenced to confirm the partial cDNAs of β1- and β2-spectrins. Products were subcloned into pGEX6p-1 for bacterial over-expression. Novel ankyrin-G SBD variants were generated by ligating *Ank3* fragments PCR-amplified with primer sets 5 and 6 into pcDNA3.1. *Ank3* fragments with novel splice junctions lacking exon 31 were PCR-amplified with primers (`ATGACGGAGGAAATTATGACCAC, GGAGAGAGAACTTATCGTCCTT`). *Ank3* fragments PCR-amplified with primer set 6 used primers (`GAACTTATCGTCCTTCGGAGC, TCATGGTGATCGGCTTATG`). Novel ankyrin-G CTD variants were PCR amplified with the primer set (`ATGAGGATGGCGATAGTAGCCG, AACTTCTCCCTGCTTAGGCTC`) and subcloned into the lenti-viral vector pCDH1-MCS (Systems Biosciences).

*In vitro* binding assays {#sec006}
-------------------------

GST-fusion proteins of β1- and β2-spectrins were over-expressed and purified as described \[[@pone.0128177.ref013]\]. *In vitro* translated (IVT) products of AnkG-SBD variants (wt, ΔE31, ΔE28-31) were prepared using TnT T7-Coupled Reticulate Lysate System (Promega) and binding assays were performed as described \[[@pone.0128177.ref013]\].

Immunoblot analysis of ankyrin-G expression {#sec007}
-------------------------------------------

Frozen mouse cerebellum and heart were pulverized with a mortar and pestle and resuspended in 4 volumes of RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM PMSF and 1X protease inhibitor cocktail (Sigma Aldrich)). Lysate was homogenized with a dounce homogenizer, incubated on ice for 30 minutes, and then centrifuged at 20,000 x g for 15 minutes at 4°C. Supernatants were collected and protein lysates were separated by SDS-PAGE and transferred to nitrocellulose membrane (GE Healthcare). Membranes were incubated with affinity-purified ankyrin-G IgG (0.5 μg/ml) or Na^+^/H^+^ exchange regulatory factor (NHERF) (Sigma Aldrich) overnight at 4°C. Immunoreactive polypeptides were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce).

Isolation and imaging of individual adult mouse cardiomyocytes {#sec008}
--------------------------------------------------------------

Adult mouse cardiomyocytes were isolated as described previously \[[@pone.0128177.ref015]\]. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Welfare Committee at University of Texas Health Science Center at Houston (permit \#13--083). 3 month-old mice were anesthetized with intraperitoneal injection of tribromoethanol-Avertin (Sigma T48402) at 0.2 ml/10g of 1.25% solution, euthanized by removing the heart, and all efforts were made to minimize suffering. Hearts from wild type mice were placed in ice-cold saline and the aorta was cannulated. Hearts were first perfused with warm perfusion buffer for a few minutes, followed by perfusion with digestion buffer containing collagenase (Worthington, Collagenase type II 305U/mg). Once digested, hearts were minced and triturated, then centrifuged at 300 rpm x 5 minutes at 4°C. Supernatant was removed and cells were immediately fixed by adding ice-cold 100% ethanol in excess, and kept in -20°C until use.

Cells were washed in ice-cold phosphate-buffered saline (PBS, pH 7.4) 3x. Cells were then blocked with 5% normal goat serum and 0.075% TritonX-100 for 30 minutes at room temperature then incubated in primary antibodies overnight at 4°C. Primary antibodies used were: voltage-gated sodium channel Na~V~1.5 (1:500, \[[@pone.0128177.ref016]\], ankyrin-G (1:50, clone N106/20, UC Davis/NIH NeuroMab Facility), α-actinin (1:200, Sigma), and ankyrin-G (1:50, \[[@pone.0128177.ref017]\]). Secondary antibodies used were goat anti-rabbit conjugated to Alexa Fluor 488 and goat anti-mouse conjugated to Alexa Fluor 568 (1:500, LifeTechnologies). Hoechst 33258 (1:1000, LifeTechnologies) was used for nuclear staining after removal of the secondary antibody. ProLong Gold Antifade reagent (LifeTechnologies) was used for mounting coverslips. Images were obtained with a Nikon A1 confocal microscope (Nikon, Melville, NY) equipped with 40X oil, numerical aperture 1.4 objective.

Isolation and viral transduction of mouse neonatal cardiomyocytes {#sec009}
-----------------------------------------------------------------

Primary cultures of cardiomyocytes were prepared from P1 wild-type neonatal mouse hearts as previously described \[[@pone.0128177.ref018]\]. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Welfare Committee at University of Texas Health Science Center at Houston (permit \#13--083). Neonatal mice were euthanized by decapitation and all efforts were made to minimize suffering. Briefly, hearts were enzymatically and mechanically dispersed in Ham's F10 with 0.05% trypsin for two 15-minute incubations at 37°C followed by a 50-minute incubation in collagenase type II (0.2mg/mL, Sigma). Pelleted and dispersed myocytes were pre-plated for 4 hours at 37°C in complete growth media (40% Ham's F-10, 40% Dulbecco's Modified Eagle's Media with high glucose, and 20% fetal bovine serum). Non-adherent cardiomyocytes were pelleted, re-suspended in fresh complete growth media, and plated on MatTek plates (MatTek Corporation, Ashland, MA). 48 hours later, the media was replaced with defined growth media (1 μg/mL insulin, 5μg/mL transferrin, 1nM LiCl, 1nM NaSeO~4~, 0.1nM thyroxine) to prevent overgrowth of fibroblasts. Following 3 days in culture, cardiomyocytes were transduced with lenti-viral constructs of GFP-tagged full-length or truncated AnkG-CTDs, and imaged 4 days later by confocal microscopy. Primary antibodies used were: GFP (1:500, SC-8334, Santa Cruz Antibodies), α-actinin (1:1000, Sigma), and ankyrin-G (1:500, \[[@pone.0128177.ref017]\]).

Statistical Analysis {#sec010}
--------------------

Statistical analyses were performed using Prism (GraphPad Software, Inc; version 6.0). One-way ANOVA followed by Tukey's multiple comparison test or unpaired Student's *t*-test was used to analyze C~T~ values from qt-PCR experiments to determine whether the expression differences in splice junctions were statistically significant.

Results {#sec011}
=======

The heart expresses a heterogeneous population of ankyrin-G isoforms {#sec012}
--------------------------------------------------------------------

To determine if the heart expresses more than one ankyrin-G isoform, we performed immunoblot analysis of ankyrin-G protein expression in heart using a polyclonal antibody to ankyrin-G \[[@pone.0128177.ref010]\]. To confirm the specificity of the ankyrin-G antibody, we also performed immunoblot analysis of ankyrin-G expression in wild-type and ankyrin-G null cerebellums. In contrast to ankyrin-G null cerebellums, wild-type cerebellums express numerous ankyrin-G immunoreactive polypeptides ([Fig 1A](#pone.0128177.g001){ref-type="fig"}). Likewise, we detected multiple ankyrin-G isoforms in heart lysate from adult mice.

![Immunoblot and immunofluorescent detection of ankyrin-G isoforms in heart.\
(**A**) Ankyrin-G immunoblot demonstrates expression of different isoforms in heart (arrows). Loss of ankyrin-G immunoreactive polypeptides in ankyrin-G null cerebellums demonstrates antibody specificity. NHERF1 immunoblot demonstrates similar loading of protein lysates. (**B**) Immunofluorescent co-localization of ankyrin-G (monoclonal antibody) and the voltage-gated sodium channel Na~V~1.5 at intercalated discs of an individually isolated adult cardiomyocyte (white arrows and highlighted in the inset). (**C**) Immunofluorescent co-localization of ankyrin-G (polyclonal antibody) and α-actinin at Z-lines of individually isolated adult cardiomyocytes (white arrows and highlighted in the inset). Scale bar represents 10 microns.](pone.0128177.g001){#pone.0128177.g001}

We performed confocal microscopy to evaluate ankyrin-G subcellular localization with resident proteins of the intercalated disc and T-tubules in cardiomyocytes isolated from adult mice. Using a monoclonal antibody to ankyrin-G, we find a population of ankyrin-G co-localizes with the voltage-gated sodium channel Na~V~1.5 at the intercalated discs ([Fig 1B](#pone.0128177.g001){ref-type="fig"}). The commercially available monoclonal antibody was generated against the spectrin-binding, death, and C-terminal domains of human ankyrin-G. Additionally, using a polyclonal antibody to ankyrin-G, we demonstrate another population of ankyrin-G co-localizes with α-actinin, a cytoskeletal component of the Z-line that underlies 60% of the T-tubular network ([Fig 1C](#pone.0128177.g001){ref-type="fig"}) \[[@pone.0128177.ref019]\]. The polyclonal antibody was generated against the death and C-terminal domains of human ankyrin-G \[[@pone.0128177.ref010]\]. Taken together, these data demonstrate that the heart expresses a heterogeneous population of ankyrin-G isoforms that localize to the intercalated disc and/or Z-lines of individual myocytes.

Identification of novel *Ank3* exons and splice variants in cardiac mRNA {#sec013}
------------------------------------------------------------------------

To examine *Ank3* mRNA expression and identify novel alternative splice variants, we performed reverse-transcriptase PCR on ventricular mRNA using nine overlapping primer sets ([Table 1](#pone.0128177.t001){ref-type="table"}) that spanned the length of the *Ank3* gene ([Fig 2A](#pone.0128177.g002){ref-type="fig"}). The integrity of the mRNA was evaluated by ethidium bromide staining of a 1% agarose gel. The presence of sharp 28S and 18S rRNA bands at a ratio of 2:1 and the absence of low molecular weight smears demonstrate that the mRNA was intact and not degraded ([S1 Fig](#pone.0128177.s001){ref-type="supplementary-material"}). We identified a variety of novel alternative *Ank3* mRNA transcripts including: 10 variants of the membrane-binding domain, 12 iterations of the spectrin-binding domain, and 6 permutations of the C-terminal regulatory domain ([Fig 2B](#pone.0128177.g002){ref-type="fig"}). The splicing patterns include exon-skipping (exon 16 in MBD), use of alternative 5'-donor site (exon 39 in CTD) or alternative 3'-acceptor site (exon 28 in SBD), and excision of internal exonic sequence (exon 44 in CTD). We also identified two new exons in the spectrin-binding domain (exons 27 and 30). Neither exon alters the open reading frame nor do they disrupt the minimal spectrin-binding domain. [Table 2](#pone.0128177.t002){ref-type="table"} includes an updated nomenclature for *Ank3* exon organization in addition to the lengths of individual exons and the intervening introns. Transcripts encoding the muscle-specific ankyrin-G isoforms that lack the membrane-binding domain (e.g. G107) initiate at the alternative start site in exon 25 and include exons 46--49. We have limited the scope of this study to the alternative splicing of full-length *Ank3* transcripts.

10.1371/journal.pone.0128177.t001

###### *Ank3* primer sets.

![](pone.0128177.t001){#pone.0128177.t001g}

  \#   5' primer                     3' primer
  ---- ----------------------------- ----------------------------
  1    ATGAGTGAAGAGCCAAAGGAGAAG      GCAACGTGTAAGGGAGTGATGTC
  2    CTGCTCGAGAACGACACGAAGG        GAGCCCCATCTTGGACCAGATAC
  3    GGTGCATCTATTCAAGCCGTAACC      GTTGACATTCGCGTTTCTACTCAG
  4    GCCAAATACGGAAAGCTTGAAGTC      CTGAGATATATTCCCCATCACTGAGC
  5    GAAGGTCGTGACGGAGGAAATTATG     CCGAAGGACGATAAGTTCTCTCTCC
  6    CAGCGGACACGTTAGATAATGTGAAC    CTTGTACCCATTGGACACGCCTTC
  7    CTTATCGTCCTTCGGAGCGAGAAC      CAAGCTGCTGTCCTCCTTTGG
  8    GTGTGTCTTTCACAACCAACGTTTCAG   CCAGCAGAGTTACAATGTCTATCCGG
  9    GATATCAGGATGGCGATAGTAG        GATTTCCTTCTTCGTCTTCACC

10.1371/journal.pone.0128177.t002

###### *Ank3* exon organization.

![](pone.0128177.t002){#pone.0128177.t002g}

  Exon \#   Previous exon \#   5'-splice   3'-splice   Length /CDS (bp)   3' intron (bp)   Domain   Comments
  --------- ------------------ ----------- ----------- ------------------ ---------------- -------- ------------------------------------
  1a                                       AGCAG/gt    357/57             85099            MBD      Start
  2a                           ag/GGTGA    AAAAG/gt    39                 49954            MBD      
  1b        1                              AAAAG/gt    577/63             172527           MBD      Start
  1c                                       AAAAG/gt    861/114            79015            MBD      Start
  1d                                       AAGAA/gt    358/36             1942             MBD      Start
  1e                                       AGAGG/gt    343/24             20966            MBD      Start
  2b        2                  ag/TCTGA    ACCAG/gt    102                430              MBD      ANK Repeat 1
  3         3                  ag/AATGG    CAAAG/gt    99                 199              MBD      ANK Repeat 2
  4         4                  ag/AAAGG    CTCAG/gt    99                 6425             MBD      ANK Repeat 3
  5         5                  ag/AATGG    CAGAG/gt    99                 6501             MBD      ANK Repeat 4
  6         6                  ag/GACGG    CAAAG/gt    186                1924             MBD      ANK Repeat 5, 6
  7         7                  ag/AGTGG    CACGG/gt    99                 25689            MBD      ANK Repeat 7
  8         8                  ag/AATGA    CCAGG/gt    99                 17180            MBD      ANK Repeat 8
  9         9                  ag/GACGG    CCAAG/gt    99                 3518             MBD      ANK Repeat 9
  10        10                 ag/AATGG    CCCTG/gt    198                3590             MBD      ANK Repeat 10, 11
  11        11                 ag/AATGG    CCGAG/gt    99                 2941             MBD      ANK Repeat 12
  12        12                 ag/TCGGG    ATGTG/gt    99                 1964             MBD      ANK Repeat 13
  13        13                 ag/AGAGG    CTAAG/gt    99                 2369             MBD      ANK Repeat 14
  14        14                 ag/GATGA    CAAAG/gt    198                4376             MBD      ANK Repeat 15, 16
  15        15                 ag/AAGGG    GGAAG/gt    99                 293              MBD      ANK Repeat 17
  16        16                 ag/AGCGG    CAAAG/gt    99                 7084             MBD      ANK Repeat 18
  17        17                 ag/AATGG    ATAAG/gt    198                925              MBD      ANK Repeat 19, 20
  18        18                 ag/AGCGG    CAAAG/gt    99                 4497             MBD      ANK Repeat 21
  19        19                 ag/ATGGG    CGAAG/gt    99                 89               MBD      ANK Repeat 22
  20        20                 ag/AATGG    CTGTG/gt    99                 667              MBD      ANK Repeat 23
  21        21                 ag/AATGG    CCACT/gt    96                 5108             MBD      ANK Repeat 24
  22        22                 ag/ACCAT    TGAAG/gt    73                 177              SBD      
  23        23                 ag/TAAGG    AGAAG/gt    63                 15927            SBD      
  24        24                 ag/GTGAT    GAAAA/gt    54                 1628             SBD      
  25        25                             ACACA/gt    384/16             1503                      3' intron to ATG of E25/alt. start
  26        26                 ag/GTGAA    GCCAG/gt    124                4575/4590        SBD      
  27                           ag/TCCCA    ATAAG/gt    12                 2935             SBD      new exon
  28        27                 ag/CCTCC    AGCAG/gt    103                18455            SBD      
  28'                          ag/TTCGG    AGCAG/gt    88                 18455                     5'-truncated exon 28
  29        28                 ag/CACCT    TCTGG/gt    107                2381             SBD      
  30                           ag/CTGCT    TCAAG/gt    33                 2453             SBD      new exon
  31        29                 ag/GTTTC    TTAGG/gt    225                2767             SBD      ZU5 motif
  32        30                 ag/CCCCG    TGAAG/gt    155                14649            SBD      ZU5 motif
  33        31                 ag/AACTC    TCCAG/gt    212                2114             SBD      
  34        32                 ag/GCTCA    CACAG/gt    208                1457             SBD      
  35        33                 ag/GAGGC    GCCAG/gt    97                 661              SBD      
  36        34                 ag/ATTCT    TTGAG/gt    229                618              SBD      
  37        35                 ag/GTTCT    TCAAG/gt    126                828              DD       
  38        36                 ag/ATCAG    AAAAG/gt    123                1721             DD       
  39        37                 ag/GCTGA    CATGA/gt    82                 3891             DD       
  39'                          ag/GCTGA    TTTAC/gt    46                 3927                      3'-truncated exon 39
  40                           ag/TTGAA    GACAG/gt    7694               589                       brain-specific exon
  41        38                 ag/GTCCG    GACAG/gt    75                 3648             CTD      
  42        39                 ag/AGCTG    CACAA/gt    132                1128             CTD      
  43        40                 ag/CTGAT    TGATG/gt    144                2424/3012        CTD      
  44        41                 ag/GTCAC    GACAG/gt    679                2008             CTD      
  44'                          ag/GTTGG    GACAG/gt    91                 2008             CTD      5'-truncated exon 44
  45        42                 ag/CTCTG    CTAAG/gt    382                1808             CTD      
  46                           ag/CAGGT    ACAAG/gt    54                 1924             CTD      18-aa insert
  47                           ag/GACTT    TAAAG/gt    87                 5107             CTD      76-aa insert
  48                           ag/GGGGA    GAAAA/gt    84                 135              CTD      76-aa insert
  49                           ag/ATCAC    ACGTG/gt    57                 1321             CTD      76-aa insert
  50        43                 ag/CAGGG    TCCAG/gt    86                 8178             CTD      Stop
  51        44                 ag/GACCA    TTCCT       3605                                         Non-coding

Table includes current and previous exon numbers (NM_146005.3), adjacent nucleotide sequences to 5'- and 3'- splice junctions, exon length (and length of coding sequence CDS for first exons), intron length, functional domain encoded by the exon, and any additional comments. NCBI accession numbers for the first exons are as follows: exon 1a: BB614215, exon 1b: BX520427, exon 1c: CD802881, exon 1d: DV047480, exon 1e: AI614790, and exon 25: BB628284.

![Exon organization and alternative splicing of *Ank3* gene.\
(**A**) Diagram of ankyrin-G exon organization and nine overlapping PCR primer sets used to amplify cardiac-specific *Ank3* alternative transcripts. Ankyrin functional domains are indicated. MBD: membrane-binding domain, SBD: spectrin-binding domain, DD: death domain, CTD: C-terminal domain. The large (7694 bp) brain-specific exon corresponds to exon 38. (**B**) Diagram of alternative *Ank3* splice variants encoding the MBD, SBD, and CTD. In the MBD, 5 alternative first exons (1a-1e) were detected. Lengths of intervening intronic sequences are labeled in kilobases (k). In the SBD, two novel exons (27 and 30) were identified and exon numbering has been adjusted accordingly (exon 40 is now the brain-specific exon). Exon 25 (in red) encodes the alternative start site for truncated ankyrin-G isoforms that lack MBDs (e.g. AnkG-107). In the CTD, alternative splicing of exons 46--49 (highlighted in gray) was not addressed in this study. (**C**) Full-length exon-exon boundary spanning primers are necessary to amplify PCR products: *Ank3* splice junctions of exons 26/28 and 26/t28 (truncated) (first panel) and exons 43/44 and 43/t44 (second panel).](pone.0128177.g002){#pone.0128177.g002}

To determine the relative mRNA expression of particular *Ank3* transcripts, we designed exon-exon boundary spanning primers that selectively PCR amplify transcripts based on their unique exon junctions. Specifically, one PCR primer spans the junction of two adjacent exons and the full-length primer is required to amplify a PCR product ([Fig 2C](#pone.0128177.g002){ref-type="fig"}). PCR conditions (primer lengths, annealing temperatures) are optimized for quantitative real-time PCR analysis such that the efficiency of each primer set falls within the range of 90--110%. Nucleotide sequences, annealing temperatures, and primer efficiencies for all 28 primer sets are listed in [S1 Table](#pone.0128177.s002){ref-type="supplementary-material"}. We have previously used this technique to demonstrate the expression of alternative *ANK2* transcripts in mouse and human hearts \[[@pone.0128177.ref013]\].

Expression of five *Ank3* alternative first exons in various tissues {#sec014}
--------------------------------------------------------------------

The *Ank3* gene has five first exons within \~409 kb of the second exon. To determine the relative expression of each first exon in heart, we performed quantitative real-time PCR analysis using exon-exon boundary spanning primers that selectively detect specific exon junctions. The expression of each first exon is represented relative to the expression of the other first exons. Therefore, the sum of expression of exons 1a, 1b, 1c, 1d, and 1e equals 100%. Rare alternative splice junctions (\< 1%) are indicated by gray, dashed lines ([Fig 3A](#pone.0128177.g003){ref-type="fig"}) and not included in the summation, although the primary data is provided in [S2 Table](#pone.0128177.s003){ref-type="supplementary-material"}.

![Relative mRNA expression of alternative *Ank3* first exons.\
(**A**) Diagram of alternative splicing of 5 first exons of the *Ank3* gene. Gray dashed lines represent rare alternative spliced junctions (\<1%). (**B**) qt-PCR analysis of hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression (measured as cycle threshold number) in ventricle, atria, skeletal muscle, brain, and kidney from three mice (labeled M1--M3). (**C**) Relative mRNA expression of alternative first exons was measured in heart (ventricle and atria), skeletal muscle, brain, and kidney by qt-PCR analysis. Bar graphs represent technical replicates of qt-PCR samples and error bars represent standard deviations. Statistical analysis was performed with one-way ANOVA with Tukey's multiple comparison test (\*\*\* *p*-value ≤0.001, ns: not significant) to assess the significance of expression differences between different splice variants (i.e. 1a vs. 1b).](pone.0128177.g003){#pone.0128177.g003}

In heart, we compared the relative expression of the first exons in ventricular and atrial mRNA isolated from three mouse hearts. We found that *Ank3* transcripts with first exons 1b, 1c, or 1d are more abundant than transcripts with first exons 1a or 1e ([Fig 3C](#pone.0128177.g003){ref-type="fig"}). In addition to heart, *Ank3* gene products have been detected in numerous tissues including skin, skeletal muscle, lung, kidney, and brain \[[@pone.0128177.ref001]--[@pone.0128177.ref006], [@pone.0128177.ref020]--[@pone.0128177.ref022]\]. To determine if first exons display tissue-specific expression, we measured the relative expression of the first exons in mRNA transcripts isolated from kidney, brain, and skeletal muscle (whole tissue). In skeletal muscle, the relative expression of *Ank3* transcripts with first exon 1b is \~60%, 1c is \~20%, and 1d is \~10% ([Fig 3C](#pone.0128177.g003){ref-type="fig"}). Ank3 transcripts with first exons 1a and 1e are expressed less than 5% in skeletal muscle. In kidney and brain, we found that *Ank3* transcripts with first exons 1b and 1c are more abundant than transcripts with first exons 1a and 1e ([Fig 3C](#pone.0128177.g003){ref-type="fig"}). Interestingly, *Ank3* transcripts with first exon 1d were virtually undetectable in kidney and brain. Exon 1d was also undetected in mRNAs isolated from cerebellum and lung (data not shown). To validate the similarity of mRNA quantity and quality isolated from the different mouse tissues, we demonstrated equivalent expression of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) in mRNA samples from the ventricle, atria, skeletal muscle, brain, and kidney ([Fig 3B](#pone.0128177.g003){ref-type="fig"}).

Cardiac expression of *Ank3* splice variants encoding ankyrin-G MBD {#sec015}
-------------------------------------------------------------------

*Ank3* exons 1--21 encode the ankyrin-G MBD ([Table 2](#pone.0128177.t002){ref-type="table"}). During the screen for alternative transcripts, we identified four alternative splice variants (± exon 16 and ± exon 18) of the MBD ([Fig 4A](#pone.0128177.g004){ref-type="fig"}). To measure the relative expression of these alternative splice variants, we performed quantitative real-time PCR using exon-exon boundary spanning primers on mRNAs isolated from mouse ventricular tissue. We found that splice variants including exon 16 or exon 18 are about four-fold more abundant than transcripts that lack these exons ([Fig 4B](#pone.0128177.g004){ref-type="fig"}).

![Relative mRNA expression of alternative *Ank3* transcripts encoding ankyrin-G MBD.\
(**A**) Diagram of *Ank3* alternative splicing in ankyrin-G MBD. (**B**) Expression of *Ank3* mRNA transcripts ± exon 16 or ± exon 18 was measured in three mouse hearts using qt-PCR analysis with exon-exon boundary spanning primers. Bar graphs represent technical replicates of qt-PCR samples and error bars represent standard deviations. Statistical analysis was performed with unpaired Student's T-test (\*\*\* *p*-value ≤0.001).](pone.0128177.g004){#pone.0128177.g004}

Cardiac expression of *Ank3* splice variants encoding ankyrin-G SBD {#sec016}
-------------------------------------------------------------------

During the screen for cardiac-specific *Ank3* transcripts, we identified two new exons (27 and 30) in the SBD ([Fig 5A](#pone.0128177.g005){ref-type="fig"} and [Table 2](#pone.0128177.t002){ref-type="table"}). We also identified 12 novel alternative spliced transcripts. We measured the relative expression of each splice junction by quantitative real-time PCR. Four splice junctions (E22/24, E26/32, E30/31, E29/32) are so rare (\< 1%) that we excluded them from the determination of relative mRNA expression, although the primary data is provided [S2 Table](#pone.0128177.s003){ref-type="supplementary-material"}. We identified three *Ank3* transcripts with unique 3'-splice junctions with exon 22: E22/23, E22/24, and E22/26. Expression of E22/24 is less than 1%, while E22/26 is \~1.5 fold more abundant than E22/23 ([Fig 5B](#pone.0128177.g005){ref-type="fig"}). We also identified three *Ank3* transcripts with unique 5'-splice junctions with exon 26: E22/26, E23/26, and E24/26. While both E22/26 and E23/26 are equally abundant (\~45% each), E24/26 is much less abundant (\~5%). Lastly, we identified three *Ank3* transcripts with unique 5'-splice junctions with exon 28: E26/28, E26/tr28 (tr:truncated), and E27/28. Interestingly, exon 27 is one of the newly identified exons and transcripts containing this exon (E27/28) are the most abundant (\~55--60%), followed by transcripts with the splice junctions of E26/tr28 (\~25%) and then E26/28 (\~15%).

![Relative mRNA expression of alternative *Ank3* transcripts encoding ankyrin-G SBD.\
(**A**) Diagram of *Ank3* alternative splicing in ankyrin-G SBD. Newly identified exons are labeled in black and the alternative first exon (E25) is labeled in red. Gray dashed lines represent rare alternative spliced junctions (\<1%). (**B**) Expression of various *Ank3* mRNA transcripts was measured in three mouse hearts using qt-PCR analysis with exon-exon boundary spanning primers. Bar graphs represent technical replicates of qt-PCR samples and error bars represent standard deviations. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test or unpaired Student's T-test (\*\*\* *p*-value ≤0.001, ns: not significant).](pone.0128177.g005){#pone.0128177.g005}

Two ankyrin-G SBD isoforms lack β-spectrin binding {#sec017}
--------------------------------------------------

In the spectrin-binding domain, the ZU5 motif represents the minimal β-spectrin binding domain and is encoded by exons 31 and 32 \[[@pone.0128177.ref023]\]. We identified two novel alternative *Ank3* splice variants that lacked exon 31. While these transcripts in heart are rare (\< 1%) ([S2 Table](#pone.0128177.s003){ref-type="supplementary-material"}), we evaluated β-spectrin binding to GST-fusion proteins of these SBD isoforms (SBDΔE31 and SBDΔE28--31) ([Fig 6A](#pone.0128177.g006){ref-type="fig"}). The ankyrin-binding domain has been mapped to spectrin repeats 14 and 15 \[[@pone.0128177.ref024]--[@pone.0128177.ref026]\]; therefore, we generated GST-fusion proteins of spectrin repeats 13 through 17 for both β1- and β2-spectrins. Briefly, *in vitro* translated and ^35^S-labelled SBD protein fragments were incubated with GST, GST β1-spectrin, or GST β2-spectrin. Glutathione sepharose precipitated radiolabelled protein complexes that were resolved by SDS-PAGE and visualized by autoradiography. While β1- and β2-spectrins bind wild-type SBD, the SBD displays greater binding capacity for β1-spectrin than for β2-spectrin ([Fig 6B](#pone.0128177.g006){ref-type="fig"}). In contrast, neither SBDΔE31 nor SBDΔE28--31 bound to spectrin demonstrating that partial loss of the ZU5 motif completely disrupts SBD binding to β-spectrin. Coomassie Blue Stain demonstrated equal loading of GST fusion proteins β1- and β2-spectrin ([Fig 6C](#pone.0128177.g006){ref-type="fig"}).

![Alternative ankyrin-G SBD isoforms do not bind β-spectrin.\
(**A**) Diagram of *Ank3* exon organizations for two rare ankyrin-G SBD variants (ΔE31 and ΔE28--31). Both variants lack a portion of the ZU5 motif. (**B**) β1-spectrin and β2-spectrin (repeats 13 to 17) binding to ankyrin-G SBDs (wildtype, Δ31, Δ28--31) was measured by *in vitro* binding assays. Label is the unbound *in vitro* translated SBD products. (**C**) Coomassie Blue Stain demonstrates equal loading of GST-fusion proteins β1- and β2-spectrins.](pone.0128177.g006){#pone.0128177.g006}

Cardiac expression of *Ank3* splice variants encoding ankyrin-G CTD {#sec018}
-------------------------------------------------------------------

The focus of this study is to identify novel variants of full-length ankyrin-G. *Ank3* exons 46, 47, 48, and 49 encode an obscurin-binding domain that is uniquely expressed in truncated ankyrin-G isoforms that were initially characterized in skeletal muscle (e.g. G107) \[[@pone.0128177.ref002]--[@pone.0128177.ref004]\]. We were unable to detect these exons in full-length *Ank3* transcripts in heart; therefore, the characterization of alternative splicing of this domain was excluded from this study.

We identified six novel *Ank3* splice variants of the CTD ([Fig 7A](#pone.0128177.g007){ref-type="fig"}). Exon 40 was never detected in any cardiac transcripts and we identified two splice junctions that excise this brain-specific exon. The splice junction of E39/41 is predominant in heart and the use of an alternative 5'-donor site within exon 39 is exceedingly rare (\< 1%) ([S2 Table](#pone.0128177.s003){ref-type="supplementary-material"}). We identified three alternative splice variants of exon 44: E43/44, E43/tr44, and a medial excision of 267 base pairs from exon 44. Exon 44 is 679 bp in length and the 5'-truncation removes 588 bp (tr44). The splice variant E43/44 is more abundant than E43/tr44 (\~55% versus \~40%), while the splice variant that lacks 267 base pairs in the middle of exon 44 is less common (\~5%) ([Fig 7B](#pone.0128177.g007){ref-type="fig"}).

![Relative mRNA expression of alternative *Ank3* transcripts encoding ankyrin-G CTD.\
(**A**) Diagram of *Ank3* alternative splicing in ankyrin-G CTD. Exon 40 is the large (7694 bp) brain-specific exon, while exon 51 contains non-coding sequence. Exons 46--49 are expressed in truncated ankyrin-G isoforms that lack membrane-binding domains. Gray dashed lines represent rare alternative spliced junctions (\<1%). (**B**) Expression of various *Ank3* mRNA transcripts with different iterations of exon 44 (full-length, 5'-truncated, medially truncated) was measured in three mouse hearts using qt-PCR analysis with exon-exon boundary spanning primers. Bar graphs represent technical replicates of qt-PCR samples and error bars represent standard deviations. Statistical analysis was performed with one-way ANOVA with Tukey's multiple comparison test (\*\*\* *p*-value ≤0.001).](pone.0128177.g007){#pone.0128177.g007}

Exogenous ankyrin-G CTD isoforms display similar subcellular expression as endogenous ankyrin-G {#sec019}
-----------------------------------------------------------------------------------------------

Ankyrin-G is localized to the intercalated disc and Z-lines in adult ventricular cardiomyocytes (Fig [1B](#pone.0128177.g001){ref-type="fig"}--[1C](#pone.0128177.g001){ref-type="fig"}). We have previously demonstrated that the C-terminal domain of ankyrin-B plays an important role in targeting this related adaptor protein to the sarcomeric M-line in cardiomyocytes \[[@pone.0128177.ref027]\]. To assess whether the C-terminal domain of ankyrin-G contains targeting motifs, we evaluated the subcellular localization of the two most abundant CTD variants in virally transduced neonatal cardiomyocytes. Lenti-viral expression in neonatal cardiomyocytes is preferable to adult cardiomyocytes because they survive in culture for 7--10 days compared to adult myocytes, which survive for \~24 hours. Lenti-viral constructs with GFP tags were made of the ankyrin-G CTD containing the full-length exon 44 (679 bps) or the 5'-truncated exon 44 (lacking 588 bps) ([Fig 8A](#pone.0128177.g008){ref-type="fig"}). Expression of lenti-viral constructs was confirmed by immunoblot analysis of the GFP tag ([Fig 8B](#pone.0128177.g008){ref-type="fig"}). We evaluated the co-localization of these CTD variants to α-actinin in neonatal cardiomyocytes. Both variants displayed diffuse cytosolic localization and lacked the defined patterning of sarcomeres. Moreover, both variants displayed similar subcellular distributions as endogenous ankyrin-G, which was detected using the polyclonal ankyrin-G antibody ([Fig 8C](#pone.0128177.g008){ref-type="fig"}). One of the limitations of neonatal cardiomyocytes as a model system is that they lack fully developed subcellular domains, which may be required for the proper targeting of ankyrin-G.

![Subcellular localization of ankyrin-G CTD isoforms in neonatal cardiomyocytes.\
(**A**) Diagram of lenti-viral GFP-tagged CTD variants with full-length or truncated exon 44. (**B**) GFP immunoblot analysis demonstrating expression of lenti-viral constructs. (**C**) Immunofluorescent co-localization of GFP-tagged CTD variants (fl-E44-GFP and tr-E44-GFP) with Z-line resident protein α-actinin in neonatal cardiomyocytes. Bottom panels represent localization of endogenous ankyrin-G in reference to α-actinin. Scale bar represents 10 microns.](pone.0128177.g008){#pone.0128177.g008}

Discussion {#sec020}
==========

This study is the first to describe a comprehensive analysis of *Ank3* expression in heart. We identified two new exons and 28 novel alternative splicing events in the *Ank3* gene. An update to the *Ank3* exon organization and nomenclature is provided in [Table 2](#pone.0128177.t002){ref-type="table"}. Using quantitative real-time PCR with exon-exon spanning primers, we demonstrate that alternative *Ank3* splice variants are expressed at similar levels in three separate hearts. Moreover, we find that expression of *Ank3* transcripts initiated with exon 1d is restricted to the heart and skeletal muscle as these transcripts are undetectable in brain, kidney, cerebellum, and lung.

The majority of alternative splicing is situated within the coding region of the spectrin-binding domain, specifically within the exons immediately 5' of the minimal spectrin-binding domain ZU5A, which is encoded by exons 31 and 32 \[[@pone.0128177.ref028], [@pone.0128177.ref029]\] (Figs [2](#pone.0128177.g002){ref-type="fig"} and [5](#pone.0128177.g005){ref-type="fig"}). The newly identified exons 27 and 30 are also alternatively spliced, but neither exon alters the open-reading frame of ankyrin-G and exon 30 is rarely expressed in cardiac transcripts ([Fig 5](#pone.0128177.g005){ref-type="fig"} and [Table 2](#pone.0128177.t002){ref-type="table"}). Interestingly, exon 30 is included in three expressed sequence tags (CO430616, CF745086, CV555908) that were isolated from neural tissue. We identified two rare alternative splice variants that remove exon 31 (junctions of exons 26 to 32 and exons 29 to 32). *In vitro* translated products of these SBD isoforms lacked binding to both β1- and β2-spectrins ([Fig 6](#pone.0128177.g006){ref-type="fig"}). Moreover, wild-type ankyrin-G SBD bound more β1-spectrin than β2-spectrin. Ankyrin-G SBD binding to β-spectrin isoforms (β1, β2, β3, and β4) has yet to be studied extensively, much less the influence of alternative splicing on this process.

We demonstrate that the heart expresses five distinct ankyrin-G isoforms by immunoblot analysis. Imaging of individual cardiomyocytes reveals the expression of two ankyrin-G subpopulations. One population co-localizes with the voltage-gated sodium channel Na~V~1.5 at the intercalated disc (ICD), while the other population localizes to the Z-line. Interestingly, the ICD population is detected using the ankyrin-G monoclonal antibody, while the Z-line population is detected with the ankyrin-G polyclonal antibody. These differences may be the result of different antigens used for antibody production. The monoclonal antibody was generated against an antigen encoded by exons 26, 28, 29, 31--39, 41--45, and 50. In addition, splicing variations present in the antigen include 5'-truncation of exon 28, 3'-truncation of exon 39, and medial excision of 267 base pairs from exon 44. The antigen for the polyclonal antibody consisted of the death and C-terminal domains, which included the full-length exon 44.

The expression of numerous ankyrin-G isoforms in a specific tissue is quite common. Understanding the function of each isoform remains a challenge, but insights into an isoform's function may be inferred from its subcellular localization. In kidney and muscle, the truncated AnkG119 isoform is located in the Golgi apparatus and is necessary for transport of sodium potassium ATPase (NKA) to the endoplasmic reticulum \[[@pone.0128177.ref001], [@pone.0128177.ref030]\]. Many alternative ankyrin-G isoforms that lack membrane-binding domains are expressed in skeletal muscle \[[@pone.0128177.ref002]--[@pone.0128177.ref004]\]. The obscurin-binding domains encoded by *Ank3* exons 46--49 in the C-terminal domain regulate the sarcolemmal localization of these isoforms \[[@pone.0128177.ref002]\]. While a previous study demonstrated skeletal muscle expression of a full-length ankyrin-G isoform with exons 46--49 \[[@pone.0128177.ref003]\], we were unable to detect a similar isoform in cardiac muscle.

To evaluate whether *Ank3* exon 44 encoded any targeting motifs, we examined the subcellular localization of the two most abundant CTD variants in neonatal cardiomyocytes. Neither isoform displayed sarcomeric localization, similar to expression of endogenous ankyrin-G (detected with the polyclonal antibody) ([Fig 8C](#pone.0128177.g008){ref-type="fig"}). While neonatal cardiomyocytes are viable to express proteins introduced by lenti-virus, they lack the elaborate T-tubular network found in adult cardiomyocytes. Proper subcellular targeting of ankyrin-G most likely requires fully developed membrane domains in adult myocytes.

Given the diversity of functions and subcellular localizations ascribed to ankyrin-G, it is not surprising that the heart expresses multiple ankyrin-G isoforms. In ventricular cardiomyocytes, ankyrin-G expression overlaps the expression of voltage-gated sodium channels (Na~V~) at the intercalated disc and T-tubules. Interestingly, the voltage-gated sodium channels display differential subcellular localization with Na~V~1.5 predominantly expressed at the intercalated disc, while the other sodium channels (Na~V~1.1, 1.3, and 1.6) are predominantly localized to the T-tubules \[[@pone.0128177.ref031]--[@pone.0128177.ref033]\]. In addition to interacting with Na~V~1.5 at the intercalated disc, ankyrin-G has also been shown to interact with plakoglobin and connexin 43 \[[@pone.0128177.ref011]\]. Whether the intercalated disc expresses a heterogeneous population of ankyrin-G isoforms is not known, but such a scenario could account for the diversity of ankyrin-G interactions. Finally, while it has been shown that ankyrin-G is required for the retention of dystrophin and β-dystroglycan at the costameres in skeletal muscle (and presumably cardiac muscle) \[[@pone.0128177.ref007], [@pone.0128177.ref008]\], the cDNA of this particular ankyrin-G isoform has yet to be characterized. Future research efforts will focus on identifying full-length *Ank3* transcripts in heart and evaluating these isoforms for specific functions.

In closing, there are tremendous opportunities for discovery in examining the splicing regulation of ankyrin genes. Our data suggests that the *Ank3* gene is subject to complex transcriptional regulation in the heart. We propose that alternative splicing of the *Ank3* gene results in a diverse population of ankyrin-G isoforms with each isoform aggregating a unique set of proteins that impart specific functionality to unique cardiomyocyte domains such as the intercalated disc, T-tubule, or costamere.
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